Señales en vivo de 039200.KQ | Maximiza tus Ganancias con Getagraph.com

Live Chart Being Loaded With Signals

Commentary (26 abr 2024 @ 02:30):

Stats
Volumen de hoy	220 773
Volumen promedio	489 261
Capitalización de mercado	1 147.42B
EPS	KRW-279.60 ( 2024-03-18 )
Próxima fecha de ganancias	( KRW0 ) 2024-05-09
Last Dividend	KRW0 ( N/A )
Next Dividend	KRW0 ( N/A )
P/E	0
ATR14	KRW58.95 (0.20%)

Volumen Correlación

Largo: -0.21 (neutral)

Corto: -0.24 (neutral)

Signal:(63.232) Neutral

Oscotec Inc. Correlación

10 Correlaciones Más Positivas

10 Correlaciones Más Negativas

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Oscotec Inc. Correlación - Moneda/Commodity

-0.17
( neutral )

-0.20
( neutral )

0.01
( neutral )

0.06
( neutral )

0.30
( neutral )

0.02
( neutral )

Oscotec Inc. Finanzas

Annual	2023
Ingresos:	KRW4.95B
Beneficio Bruto:	KRW1.23B (24.85 %)
EPS:	KRW-634.86

FY	2023
Ingresos:	KRW4.95B
Beneficio Bruto:	KRW1.23B (24.85 %)
EPS:	KRW-634.86

FY	2022
Ingresos:	KRW5.06B
Beneficio Bruto:	KRW1.57B (31.04 %)
EPS:	KRW-763.19

Financial Reports:

No articles found.

Oscotec Inc.

Oscotec Inc. operates as a clinical stage drug discovery and development company. It develops SYK inhibitor that is in Phase IIa clinical trial to treat rheumatoid arthritis and immune thrombocytopenia; FLT3 inhibitor, which is in Phase I clinical trial for the treatment of acute myeloid leukemia; and EGFR double mutation inhibitor to treat non-small cell lung cancer, as well as Anti-Tau antibody, which is in preclinical Phase for the treatment of Alzheimer's disease. The company also offers dental health products, such as bone graft comprising InduCera, BioCera-F, and SynCeraII; and membrane consisting of LysoGide and CollaGuide. In addition, it provides functional ingredients comprises OPB for osteoporosis; AIF for arthritis; SGA that enhance bone growth; and PRF-K for perio diseases. The company was formerly known as Oscotec Co., Ltd and changed its name to Oscotec Inc. in June 1999. Oscotec Inc. was founded in 1988 and is based in Seongnam, South Korea.